Holen Sie sich die Stockscreener-App
24.33
3.09%
0.73
Schlusskurs vom Vortag:
$23.60
Offen:
$23.67
24-Stunden-Volumen:
1.16M
Relative Volume:
0.97
Marktkapitalisierung:
$2.99B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
20.62
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-0.45%
1M Leistung:
+8.86%
6M Leistung:
+20.51%
1J Leistung:
+4.60%
1-Tages-Spanne:
$23.65
$24.68
1-Wochen-Bereich:
$23.27
$24.85
52-Wochen-Spanne:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.33 | 2.90B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Is Catalyst Pharmaceuticals Inc.’s growth already priced inJuly 2025 Highlights & Long-Term Capital Growth Strategies - mfd.ru
Block Trades: Is iShares Gold Trust impacted by rising ratesInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
What is Catalyst Pharmaceuticals Inc. s 5 year growth outlookWeekly Trade Summary & AI Enhanced Trading Alerts - mfd.ru
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - GlobeNewswire
Catalyst Pharmaceuticals (CPRX) Investor Outlook: A Promising 41.4% Upside Potential - DirectorsTalk Interviews
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Renewed Interest And Pocket Pivot Signal - Sahm
Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup - ChartMill
Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years - Yahoo Finance
What is the next catalyst for Oramed Pharmaceuticals Inc.July 2025 Sentiment & Stock Portfolio Risk Control - Mfd.ru
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Federated Hermes Inc. - MarketBeat
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Growth Strength And Positive Analyst Sentiment - Sahm
Aug Reactions: Is EDHL subject to activist investor interest2025 Volume Leaders & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals (CPRX)? - Sahm
Ruffer LLP Makes New Investment in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Screens as an Affordable Growth Stock - Chartmill
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: Exploring A 45% Upside Potential - DirectorsTalk Interviews
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Y Intercept Hong Kong Ltd - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - The Motley Fool
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Fresh Rare Disease Momentum And Earnings Outperformance - Sahm
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case - Chartmill
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: A 53.56% Potential Upside Beckons Investors - DirectorsTalk Interviews
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory - Insider Monkey
Campbell & CO Investment Adviser LLC Has $1.93 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
How Investors May Respond To Catalyst Pharmaceuticals (CPRX) Rare-Disease Strength And Potential Technical Breakout - Sahm
Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock” - Insider Monkey
First Week of September 18th Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
SG Americas Securities LLC Raises Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Fundamentals with a Technical Breakout Setup - Chartmill
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - sharewise.com
Short Squeeze: What is the next catalyst for Actinium Pharmaceuticals IncProfit Target & Technical Confirmation Trade Alerts - baoquankhu1.vn
Bank Watch: Is Catalyst Pharmaceuticals Inc. stock influenced by commodity pricesJuly 2025 Review & Weekly Momentum Picks - baoquankhu1.vn
Catalyst Pharmaceuticals (CPRX) Stock Analysis: A 50% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Catalyst Pharmaceuticals, Inc. Presents at JP Morgan Healthcare Conference - TradingView
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Forbes 2026 Small Cap Recognition - Sahm
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today - MSN
Will Catalyst Pharmaceuticals Inc. stock see insider buyingQuarterly Trade Summary & Daily Stock Trend Reports - ulpravda.ru
How Catalyst Pharmaceuticals Inc. stock benefits from tech adoption2025 Trading Recap & Fast Momentum Stock Entry Tips - ulpravda.ru
Does Forbes’ Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? - Yahoo Finance
How Forbes’ Small-Cap Accolade Will Impact Catalyst Pharmaceuticals (CPRX) Investors - Sahm
Will Catalyst Pharmaceuticals Inc. stock benefit from green energy trendsEntry Point & Consistent Profit Trading Strategies - Улправда
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - AOL.com
How Catalyst Pharmaceuticals Inc. stock performs in rising dollar environmentTrade Exit Report & Verified Chart Pattern Trade Signals - ulpravda.ru
Funds from operations of Catalyst Pharmaceuticals, Inc. – FWB:CN2 - TradingView — Track All Markets
Is Catalyst Pharmaceuticals Inc. stock a buy before product launchesJuly 2025 Market Mood & Real-Time Market Trend Scan - ulpravda.ru
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):